Specifics of valuation in the drug development sector

Specifika oceňování v sektoru vývoje léčiv

Jakub Mašek and Radana Šmídová

Oceňování, 2020, vol. 13, issue 1-2, 53-64

Abstract: The aim of this article is to analyse specific aspects of valuation in drug development sector. The article is reacting to recent development around SARS-CoV-2 pandemic and aims to provide valuable information to professionals from investment community interested in opportunities in pharma and biotech sector. Consequently article involves deep analysis of the industry, its dynamics and industry specifics that are determining for company valuation.

Keywords: Valuation; Pharmacy; Biotech; Intangible assets; Patent protection; Clinical trials; Oceňování; Farmacie; Práva nehmotného vlastnictví; Patentová ochrana; Klinické testování (search for similar items in EconPapers)
JEL-codes: G39 (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
http://ocenovani.vse.cz/doi/10.18267/j.ocenovani.246.html (text/html)
http://ocenovani.vse.cz/doi/10.18267/j.ocenovani.246.pdf (application/pdf)
free of charge

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:prg:jnloce:v:13:y:2020:i:1-2:id:2020_1_04:p:53-64

Ordering information: This journal article can be ordered from
Editorial office Ocenovani, Prague University of Economics and Business, W. Churchill Sq. 4, 130 67 Prague 3, Czech Republic
http://ocenovani.vse.cz

DOI: 10.18267/j.ocenovani.246

Access Statistics for this article

Oceňování is currently edited by Časopis Oceňování

More articles in Oceňování from Prague University of Economics and Business Contact information at EDIRC.
Bibliographic data for series maintained by Stanislav Vojir ().